

DATA SHEET

Micromedex: Integration with the Philips Tasy EHR

Patient safety alerts for drugs, within the workflow of physicians, pharmacists and nurses

Micromedex® is a clinical decision support (CDS) system that provides evidence-based drug, disease and patient education information at the point of care.

The integration of Micromedex into the Philips Tasy electronic health record (EHR) helps make drug interactions, IV compatibility, dosing and referential drug information accessible directly within the workflow of physicians, pharmacists and nurses, helping them improve both clinical and operational efficiency.

Micromedex is supported by an editorial board comprised of specialized healthcare professionals who evaluate medical literature with high-level reviews, using a robust editorial process, which is accredited by the National Institute for Health and Care Excellence (NICE).

Solutions that integrate with the Philips Tasy EHR:

- Micromedex Integrated Screening and Insights
- Micromedex® Clinical Knowledge Suite
InfoButton Access®



Helps improve workflow efficiency




Helps clinicians to reduce medication errors and adverse events



Helps clinical teams to improve the quality of patient care

Features of the automated drug interaction screening in Philips Tasy



How does it work?

When the clinician enters the medication order in the EHR, a pop-up displays the drug interactions found for that order.

1. Filters

The clinician can filter by severity, strength of documentation or interaction type, to limit the information displayed.

2. Alert message

The clinician can view the expected clinical outcome of the interaction, and, using their own expertise together with the clinical context of the patient, assess if the outcome is relevant and act upon it.





3. Details

The interaction detail provides evidence-based clinical management information, as well as the referencing literature related to the alert.

Drug interactions types:

- drug-drug
- drug-food
- drug-ethanol
- drug-laboratory test
- drug-tobacco
- drug-pregnancy
- drug-lactation
- drug-disease
- ingredient duplication warnings
- therapeutic class duplication warnings
- therapeutic class antagonism warnings
- general precaution warnings

Severity ratings:

-  Contraindicated
-  Major
-  Moderate
-  Minor


Strength of

documentation ratings:

- Excellent
- Good
- Fair

Automated IV compatibility screening in Philips Tasy


The IV screening service provides information to clinicians on the administration of drugs through injection. Given a list of drugs, IV screening can screen drugs for compatibility against each other. Drugs are also screened against commonly used IV solutions.



Integrated clinical knowledge from Micromedex via InfoButton Access®

Integration provides direct links from within the Philips Tasy EHR to clinically relevant information on drugs for healthcare professionals:

- Adult and pediatric dosing
- Dosing adjustments
- Off-label uses
- Adverse effects
- Monitoring
- Toxicology
- And more



About Micromedex

Micromedex by Merative is trusted by healthcare professionals across 70 countries to provide award-winning clinical decision support solutions for drug and disease information and patient education. Micromedex was named Best in KLAS 2023 (clinical decision support: point of care clinical reference), is recognized as a CMS compendium, and is accredited by NICE for its robust editorial process.

Learn more at

merative.com/clinical-decision-support

About Merative

Merative is a data, analytics and technology partner for the health industry, including providers, health plans, employers, life sciences companies and governments. With trusted technology and human expertise, Merative works with clients to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022.

Learn more at www.merative.com



© Merative US L.P. 2023. All Rights Reserved.

Produced in the United States of America
September 2023

Merative and the Merative logo are trademarks of Merative US L.P. Other product and service names might be trademarks of Merative or other companies.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on Merative's product plans and strategy as of the date of this publication, which are subject to change by Merative without notice. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from Merative, or stating or implying that any activities undertaken by you will result in any specific performance results. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

MDX-5131767144 Rev 1.0